Antibody ID	ANI0DRBTO
Antibody Name	Anti-EPHA2 mAb
Antibody Type	Monoclonal antibody (mAb)
Antibody Subtype	Humanized IgG1-kappa
Antigen Name	Ephrin type-A receptor 2 (EPHA2)					Antigen Info

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.40 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.60 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.70 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.00 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.10 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.20 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.40 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.00 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.60 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4.20 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4.20 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4.70 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	5.60 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	6.50 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	7.30 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	7.90 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	9.10 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	10.30 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	10.40 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	12.20 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	13.20 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	14.40 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	52.50 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	63.50 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	307 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.03 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	11.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.30 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 4.00 pg/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.02 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	10.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.02 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.20 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.30 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.10 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	5.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	13.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.03 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.04 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.02 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.05 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	5.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	8.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.02 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 4.00 pg/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.02 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.10 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.03 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.20 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	29.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	29.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.03 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.10 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	5.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	26.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.03 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	12.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	12.00 pg/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.10 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.20 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	7.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	20.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.00 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 4.00 pg/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 4.00 pg/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170

Ref 1	Immunomodulatory antibody-drug conjugates; 2022-07-21.